AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
11.36
+0.08 (0.71%)
At close: Sep 2, 2026, 4:00 PM EDT
11.29
-0.07 (-0.62%)
Pre-market: Sep 3, 2026, 4:00 AM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $4.05M in the quarter ending June 30, 2026, a decrease of -76.29%. This brings the company's revenue in the last twelve months to $66.17M, up 101.28% year-over-year. In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth.
Revenue (ttm)
$66.17M
Revenue Growth
+101.28%
P/S Ratio
55.63
Revenue / Employee
$117,740
Employees
562
Market Cap
3.68B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.13M | 46.30M | 160.56% |
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | 11.61M | 2.78M | 31.49% |
| Dec 31, 2018 | 8.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| Tango Therapeutics | 53.81M |
| uniQure | 18.67M |
| Relay Therapeutics | 10.35M |
ABCL News
- 12 hours ago - AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Business Wire
- 8 days ago - AbCellera rises 17.0% - TheFly
- 8 days ago - AbCellera rises 10.7% - TheFly
- 21 days ago - AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - Business Wire
- 22 days ago - AbCellera announces $200M common stock, warrants offering - TheFly
- 22 days ago - AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 22 days ago - AbCellera price target raised to $30 from $12 at Truist - TheFly
- 23 days ago - AbCellera price target raised to $25 from $13 at JonesResearch - TheFly